Lisinopril Stada, tablets 5 mg 30 pcs

Lisinopril is cardioprotective, natriuretic, vasodilatory, hypotensive.

Pharmacodynamics

A ACE inhibitor, reduces the formation of angiotensin II from angiotensin I. Reducing angiotensin II leads to a direct reduction in the release of aldosterone.

Decreases bradykinin degradation and increases prostaglandin synthesis.

Limits total peripheral vascular resistance, blood pressure (BP), preload, pulmonary capillary pressure, causes an increase in the minute blood volume and increases myocardial exercise tolerance in patients with chronic heart failure.

Dilates arteries to a greater extent than veins. Some effects are explained by the effect on tissue renin-angiotensin systems.

Long-term use reduces myocardial hypertrophy and arterial resistive walls. It improves the blood supply to the ischemic myocardium.

The ACE inhibitors prolong life expectancy in patients with chronic heart failure and slow the progression of left ventricular dysfunction in patients who have had myocardial infarction without clinical manifestations of heart failure.

The antihypertensive effect begins after approximately 6 hours and lasts for 24 hours. The duration of the effect also depends on the dose. Onset of action is after 1 h. The maximum effect is determined after 6-7 hours.

In case of arterial hypertension, the effect is noted in the first days after the start of treatment, the stable effect develops after 1-2 months. No pronounced increase in BP was observed when the drug was abruptly withdrawn.

In addition to BP reduction, lisinopril decreases albuminuria. In patients with hyperglycemia, it promotes normalization of function of damaged glomerular endothelium.

Lisinopril has no effect on blood glucose concentration in diabetic patients and does not lead to increased incidence of hypoglycemia.

Pharmacokinetics

Intake. After oral administration, approximately 25% of lisinopril is absorbed from the gastrointestinal tract.

Eating does not affect absorption of the drug. Absorption averages 30%, bioavailability 29%.
Distribution. Almost not bound to blood plasma proteins.

The maximum concentration in blood plasma (90 ng/ml) is reached after 7 hours. Permeability through the blood-brain and placental barrier is low.

Metabolism. Lisinopril is not biotransformed in the body.

Elimination. It is excreted unchanged by the kidneys. The elimination half-life is 12 hours.

Pharmacokinetics in selected patient groups

In patients with chronic heart failure the absorption and clearance of lisinopril are decreased.

In patients with renal failure, lisinopril concentrations are several times higher than plasma concentrations in volunteers, with increased time to maximum plasma concentrations and increased elimination half-life.

In elderly patients the plasma concentration of the drug and area under the curve are 2 times higher than in younger patients.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities